Observational Study
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Apr 10, 2018; 9(2): 33-41
Published online Apr 10, 2018. doi: 10.5306/wjco.v9.i2.33
Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy
Marco Galvez, Carlos A Castaneda, Joselyn Sanchez, Miluska Castillo, Lia Pamela Rebaza, Gabriela Calderon, Miguel De La Cruz, Jose Manuel Cotrina, Julio Abugattas, Jorge Dunstan, Henry Guerra, Omar Mejia, Henry L Gomez
Marco Galvez, Carlos A Castaneda, Henry L Gomez, Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru
Carlos A Castaneda, Faculty of Medicine, Universidad Peruana San Juan Bautista, Lima 15067, Peru
Joselyn Sanchez, Miluska Castillo, Lia Pamela Rebaza, Omar Mejia, Department of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru
Gabriela Calderon, Miguel De La Cruz, Jose Manuel Cotrina, Julio Abugattas, Jorge Dunstan, Department of Breast Cancer Surgery, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru
Henry Guerra, Department of Pathology, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru
Author contributions: Galvez M, Castaneda CA and Rebaza LP contributed to the conception and design of the study , performed data analysis and interpretation; Galvez M, Castaneda CA, Sanchez J, Castillo M, Rebaza LP and Mejia O performed data acquisition, as well as provided administrative, technical and material support; all authors drafted the article and made critical revisions related to the intellectual content of the manuscript, and approved the final version of the article to be published.
Institutional review board statement: This study was reviewed and approved by the Instituto Nacional de Enfermedades Neoplasicas Institutional Review Board. Personal and filiation data including identity of every patient was protected with an added code in the Excel table. This is a retrospective case series that did not have any activity or contact with the patients.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All of the authors declare no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Carlos A Castaneda, MD, MSc, Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520 Surquillo, Lima 15038, Peru. ccastaneda@inen.sld.pe
Telephone: +51-1-6204991
Received: June 28, 2017
Peer-review started: July 3, 2017
First decision: December 7, 2017
Revised: December 19, 2017
Accepted: February 5, 2018
Article in press: February 5, 2018
Published online: April 10, 2018
Core Tip

Core tip: The authors evaluated a series of 435 breast cancer (BC) patients who received neoadjuvant chemotherapy. They evaluated the association between stromal tumor-infiltrating lymphocytes levels and pCR in preneoadjuvant chemotherapy samples according to molecular subtypes. The results confirm differences in the predictive and prognostic role of stromal tumor-infiltrating lymphocytes and pathological complete response depending on the tumor subtype. Additionally, the authors evaluate the value of traditional prognostic features in every BC subset. The results increase the understanding of biomarkers in the heterogeneous scenario of BC.